

Letter to the Editor Response

Response to Letter to the Editor from Viola et al: “Calcifediol Treatment and COVID-19-Related Outcomes”

Xavier Nogues,^{1,2} José Manuel Quesada-Gomez,³ and Natalia Garcia-Giralt¹

¹IMIM (Hospital del Mar Medical Research Institute), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Barcelona 08003, Spain; ²Internal Medicine Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona 08003, Spain; and ³Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Fundación Progreso y Salud, CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Hospital Universitario Reina Sofía, Universidad de Córdoba, 14004, Córdoba, Spain

ORCID number: 0000-0001-6507-0147 (N. Garcia-Giralt).

Received: 22 July 2021; Editorial Decision: 28 July 2021; First Published Online: 31 July 2021; Corrected and Typeset: 28 August 2021.

We thank Dr. Viola and colleagues for their letter to our article (1). We agree with the authors' point that 25(OH)D levels should be assayed during the hospital stay and even after discharge. Unfortunately, because of the harsh working conditions during the first wave of the pandemic, data were obtained in only a few patients. However, a rapid rise in 25(OH)D levels was expected after acute oral calcifediol intake, according to previous studies (2) and was confirmed in in-house controls (data not shown). Vitamin D's role in immune response mechanisms appears to be regulated primarily by availability of 25(OH)D, induction of CYP27B1 in the antigen-presenting cells by the invading pathogens and, ultimately, by stimulation of 1,25(OH)₂D in the immune system (3). Potential effects of 1,25(OH)₂D by inducing antimicrobial peptides, recruitment of neutrophils, monocytes/macrophages, and dendritic cells, as well as by modulating the adaptive immune response, would help to overcome the COVID-19. Importantly, vitamin D may suppress the cytokine storm by simultaneously enhancing the innate immune system and reducing the overactivation of the adaptive immune system (3). Hence, treatment with calcifediol at higher doses is recommended to prevent worse COVID-19 outcomes as an adjuvant therapy in the hospital.

Further studies in an RCT setting are being carried out to corroborate this calcifediol effect.

Overall, there is well-established agreement that an adequate vitamin D status is necessary to maintain both musculoskeletal and general health (4,5); thus, regular monitoring of 25(OH)D levels should be considered at the population level and, in particular, in osteoporotic patients and the elderly. Accordingly, calcifediol or vitamin D supplementation should be strongly recommended to maintain adequate serum 25(OH)D levels in the general population.

Acknowledgments

Financial Support: The research was supported by Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (grants number CB16/10/00245 and CB16/10/00501); Formación en Investigación en Salud grants (grant number PI19/00033) from Instituto de Salud Carlos III (ISCIII); and European Regional Development Fund.

Additional Information

Correspondence: Natalia Garcia-Giralt, PhD, CIBER: Centro de Investigación Biomedica en Red, Barcelona, Spain. Email: ngarcia@imim.es.

Disclosure Statement: X.N. has received fees from lectures and consultancy from Amgen, UCB, and Lilly. J.M.Q.G. has received small lecture or consultancy fees from Amgen and Faes Farma (Spain). N.G.G. has nothing to declare.

References

1. Viola V, Leanza G, Tramontana F. Letter to the editor from Viola Viola: “Calcifediol treatment and COVID-19-related outcomes”. *J Clin Endocrinol Metab.* 2021:dgab565. doi:[10.1210/clinem/dgab565](https://doi.org/10.1210/clinem/dgab565)
2. Quesada-Gomez JM, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation? *Osteoporos Int.* 2018;**29**(8):1697-1711.
3. Bilezikian JP, Bikle D, Hewison M, et al. Mechanisms in endocrinology: vitamin D and COVID-19. *Eur J Endocrinol.* 2020;**183**(5):R133-R147.
4. Fan X, Wang J, Song M, et al. Vitamin D status and risk of all-cause and cause-specific mortality in a large cohort: results from the UK biobank. *J Clin Endocrinol Metab.* 2020;**105**(10):dgaa432.
5. Giustina A, Adler RA, Binkley N, et al. Controversies in vitamin D: summary statement from an international conference. *J Clin Endocrinol Metab.* 2019;**104**(2):234-240.